First-Line Atezolizumab for Metastatic Nonsquamous NSCLC

Adding atezolizumab to bevacizumab and chemotherapy improved survival in chemotherapy-naive patients with non–small-cell lung cancer, regardless of EGFR or ALK mutation status.

In a prior study, treatment with the anti–PD-L1 antibody atezolizumab combined with platinum-doublet chemotherapy demonstrated promising activity in chemotherapy-naive patients with advanced non–small-cell lung cancer (NSCLC; J Clin Oncol 2017; 35:Suppl 15:9092).

To further evaluate the effect of combining atezolizumab with chemotherapy in this setting, investigators conducted an industry-funded, international, open-label, randomized phase III trial (IMpower150) in which 1202 chemotherapy-naive patients with nonsquamous NSCLC received one of three treatments: atezolizumab-carboplatin-paclitaxel (ACP), bevacizumab-carboplatin-paclitaxel (BCP), or atezolizumab-bevacizumab-carboplatin-paclitaxel (ABCP).

Results comparing ABCP and BCP were as fol…

Reviewing Author

Anne S. Tsao, MD

Disclosures

Consultant/Advisory BoardGenentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology

RoyaltiesUpToDate

Grant/Research SupportMedimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb

Anne S. Tsao, MD

Disclosures

RoyaltiesUpToDate

First-Line Atezolizumab for Metastatic Nonsquamous NSCLC

Topics

Reviewing Author